Raghu Nathan, MD
Critical Care Medicine · Bossier City, LANPI 1457347429
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,813 and has fallen 92.8% since, to $131 in 2025.
Across 311 payments — averaging $19.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$1K
- GSK$1K
- AstraZeneca$518
- Boehringer Ingelheim$433
- Genentech USA, Inc.$331
- Insmed, Inc.$329
- plus $2K from 27 others
What the payments were for
- Food & beverage$5,70094%
- Education$3756%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 73 | $1,279 |
| GSK | 69 | $1,115 |
| AstraZeneca | 33 | $518 |
| Boehringer Ingelheim | 25 | $433 |
| Genentech USA, Inc. | 7 | $331 |
| Insmed, Inc. | 12 | $329 |
| Johnson & Johnson(2 entities) | 6 | $308 |
| Mylan Specialty L.p. | 10 | $212 |
| Gilead | 4 | $175 |
| Merck | 10 | $160 |
| Shionogi Inc | 2 | $148 |
| United Therapeutics Corporation | 7 | $145 |
| Bayer | 6 | $125 |
| Inogen, Inc. | 9 | $117 |
| Paratek Pharmaceuticals, Inc. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $69 |
| Sunovion Pharmaceuticals Inc. | 8 | $69 |
| Teva Pharmaceuticals USA, Inc. | 4 | $59 |
| Olympus America Inc. | 1 | $50 |
| Tactile Systems Technology Inc | 2 | $46 |
| Philips North America LLC | 1 | $41 |
| Pfizer | 2 | $34 |
| La Jolla Pharmaceutical Company | 2 | $33 |
| Inari Medical, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $24 |
| Electromed, Inc. | 1 | $24 |
| Amgen | 1 | $21 |
| Sanofi | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Circassia Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,076 in reported general payments places this provider in the 80th percentile of 72 critical care medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 36 | $795,656 |
| OpsumitMacitentan | 48 | $600,972 |
| AdempasRiociguat | 13 | $169,054 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 203 | $161,429 |
| OfevNintedanib Esylate | 11 | $144,069 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $11,675 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $10,886 |
| Tadalafil | 16 | $9,600 |
| EliquisApixaban | 12 | $7,572 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 39 | $1,277 |
| Ethambutol Hcl | 20 | $893 |
| Montelukast Sodium | 52 | $703 |
| Azithromycin | 14 | $298 |
| Fluticasone Propionate | 12 | $239 |
| Doxycycline Hyclate | 17 | $174 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $1,279 | $1,396,62884 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,115 | $172,315222 claims |
| BayerAdempas | $125 | $169,05413 claims |
| Boehringer IngelheimOfev, Combivent Respimat | $433 | $155,74322 claims |
| PfizerEliquis | $34 | $7,57212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 72 critical care medicine providers in Louisiana.
Other critical care medicine in Bossier City
- Gerardo San PedroBossier City$76K
- Abdulla Majid-MoosaBaton Rouge$202K
- Richard MorrisonShreveport$24K
- Laurie GrierShreveport$23K
- Fidencio DavalosLake Charles$20K
- Jonathan EatonShreveport$19K
- Steven ConradShreveport$15K
- Ahmad SharayahBaton Rouge$12K
- Ronald FieldsBaton Rouge$11K
- Jonathan VignesLafayette$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.